Description
ARA-290 Peptide Vials
| ARA 290 | |
| CAS Number | 1208243-50-8 |
| Molar Mass | 1257.31 g·mol−1 |
| Chemical Formula | C51H84N16O21 |
| IUPAC Name | (4S)-5-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-oxo-4-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoic acid |
Introduction
ARA-290 Vials represent a cutting-edge research product designed exclusively for scientific investigations. Strictly intended for research purposes, these vials contain ARA-290, a promising peptide with potential applications in various fields of medical research.
Key Characteristics
ARA-290 is a synthetic peptide derived from erythropoietin (EPO), a hormone known for its role in regulating red blood cell production. ARA-290 exhibits unique anti-inflammatory and tissue-protective properties, making it a focal point in diverse research studies.
Research Applications
ARA-290 Vials are versatile tools for investigating a range of medical conditions and biological processes. Researchers can explore its effects on chronic diseases, tissue repair mechanisms, and autoimmune disorders.
Research Benefits
ARA-290 and Chronic Diabetes
One notable research application of ARA-290 involves its potential impact on chronic diabetes. Studies have suggested that ARA-290 may modulate inflammatory responses associated with diabetes, offering a potential avenue for therapeutic interventions.
ARA-290 and Tissue Repair
ARA-290 has demonstrated promising results in promoting tissue repair. Research studies indicate its ability to enhance tissue regeneration and reduce inflammation, potentially contributing to novel approaches in the field of regenerative medicine.
ARA-290 and Autoimmune Disorders
Researchers are exploring the potential of ARA-290 in addressing autoimmune disorders. Preliminary studies suggest that ARA-290 may modulate immune responses, presenting possibilities for future investigations into autoimmune conditions.
Summary
ARA-290 Vials offer a valuable tool for researchers delving into the intricate realms of chronic diseases, tissue repair, and autoimmune disorders. With its unique characteristics, ARA-290 holds promise for advancing our understanding of these complex biological processes.
Disclaimer
This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.
Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).
Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.
Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].
IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.
References
- Schmidt RE, Feng D, Wang Q, Green KG, Snipes LL, Yamin M, Brines M. Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia. Exp Neurol. 2011 Dec;232(2):126-35. doi: 10.1016/j.expneurol.2011.05.025. Epub 2011 Aug 18. PMID: 21872588; PMCID: PMC3202026. [Read More]
- Huang B, Jiang J, Luo B, Zhu W, Liu Y, Wang Z, Zhang Z. Non-erythropoietic erythropoietin-derived peptide protects mice from systemic lupus erythematosus. J Cell Mol Med. 2018 Jul;22(7):3330-3339. doi: 10.1111/jcmm.13608. Epub 2018 Mar 23. PMID: 29570934; PMCID: PMC6010693.[Read More]
- Nairz, M., Haschka, D., Dichtl, S. et al. Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. Sci Rep 7, 13012 (2017). [Read More]
Reviews
There are no reviews yet.